Concerns Surrounding the Cervical Cancer Vaccine in India
An article by Dr. Maya Valecha critiques the Indian government’s promotion of the HPV vaccine for cervical cancer prevention. Dr. Valecha raises significant doubts about the urgency and effectiveness of the HPV vaccine rollout, questioning the scientific foundation and motives behind its widespread recommendation.
Dr Maya Valecha, Gynecologist, MD,
by training Social and political activists.
Universal Health Organization, Committee member
Dr. Maya Valecha, MD(Gynae) based in Vadodara, Gujarat has been active in left politics since her student days. She participated actively in Nav Nirman Aandolan in Gujarat with left perspective, Actively fought communal forces in 2002 & has been a staunch feminist. She did her research work on how women’s attire is oppressive in nature.
She fiercely opposed slum Demolition without any opportunity for alternative residence & livelihood in Baroda and Surat and the struggle was waged successfully.
She left medical practice as a gynecologist by 2000 to fully get involved in socio-political activities.
From the very onset of lockdown, on one hand she has been building public opinion for the Nationalisation Socialisation of the Healthcare system including drug industry, and spreading the truth about Covid-19, on the other hand.
Current Cervical Cancer Statistics
- Approximately 70,000 women die of cervical cancer annually in India, representing 20% of the global burden.
- However, these figures are intertwined with socioeconomic factors, as 40% of the world’s poor reside in India.
Misconceptions About HPV and Cervical Cancer
- Human Papillomavirus (HPV) is often cited as a primary cause of cervical cancer, with 12 oncogenic types identified. However, Dr. Valecha emphasizes that HPV is not a sufficient cause alone, as 17% of cervical cancer cases are not associated with HPV.
- A significant percentage of healthy women also carry HPV without developing cancer, indicating a self-resolving mechanism in many infections.
Contributing Factors to Cervical Cancer
Key risk factors identified include:
- High number of pregnancies.
- Malnutrition.
- Poor hygiene.
- Multiple sexual partners without protection.
- Social determinants such as poverty and related behaviors (e.g., prostitution).
Dr. Valecha highlights that while cervical cancer is the second most common cancer in women, the overall incidence is declining due to better socioeconomic conditions and hygiene.
Vaccine Efficacy Questions
- The claimed efficacy of the HPV vaccine, which targets only four of over 150 HPV types, has significant uncertainties:
- A seven-month trial period was used for the vaccine, which is insufficient for long-term conclusions.
- Concerns over the potential rise in non-target HPV strains due to the vaccine’s use.
Health Risks and Side Effects
- The vaccine has been associated with severe adverse events, including Premature Ovarian Failure and other serious conditions. However, Dr. Valecha claims there is insufficient data on these side effects.
- Issues were raised regarding the transparency of clinical trial data involving the vaccine, creating distrust among the public.
Financial Implications
- The Indian government plans to vaccinate 6.8 crore girls by 2025, costing taxpayers approximately ₹27,200 crore (around $3.3 billion), without adequate justification of necessity or efficacy.
Need for Public Awareness and Health Policy Reform
Dr. Valecha argues for:
- Increased public awareness regarding cervical cancer risks and preventive measures unrelated to vaccination.
- The promotion of public healthcare facilities over private interests that prioritize profit over health outcomes.
- Strengthening public health policy through participatory democracy to monitor and manage healthcare systems effectively.
In her latest video, Dr. Maya Valecha discussed the ongoing discussion surrounding cervical cancer in India, stressing the need to correct the stats and education in the public domain around this disease. Here are the primary things we learned from her comments:
Current Statistics and Trends
Cervical cancer represents a substantial health issue for women in India, particularly in reference to the lower portion of the uterus.
Statistically relevant data reports that mortality rates for cervical cancer are declining, with some reports indicating a –1.8% difference between 1992 and 2022 mortality rates. In 2023, the Indian Health Minister reported a total of 35,691 deaths from cervical and uterine cancer, as opposed to the sensational and exaggerated numbers in the media and public health discussion identifying 70,000 to 100,000 annual deaths.
Dr. Maya Valecha indicated this variation in reported numbers during training sessions with doctors, where it would appear the reported numbers were increasing based on points brought up in discussion rather than person-centered evidence.
Age and Demographics
It was also noted that the onset age for cervical cancer has changed; where it previously peaked for 40 to 44 years of age, and is now closer to 60 to 64 years of age. This demonstrates that cervical cancer is decreasing in younger populations.
Worldwide incidence remains low, of equal to or less than 13 to 14 cases per 100,000 with incidence occurring around age 60, which signifies the disease is predominately impacting less aged individuals
Misrepresentation in Media and Campaigns
There were some concerns expressed by Dr. Maya Valecha regarding the sensationalized representations of cervical cancer in the media and perceived political discourse, whereby more emphasis is placed upon vaccine campaigns, rather than dealing with other overarching health issues, such as child malnutrition, which is understood to contribute to 4,500 child deaths each day in India.
The focus of the campaign should shift towards educating the public on general health issues, such as nutrition and hygiene, both of which are integral to cancer prevention, as they are for a range of other health issues.
Testing and Public Health Campaigns
In terms of publicly funded health campaigns, current testing campaigns for cervical cancer ostensibly target women aged 30-60, but according to Dr. Maya Valecha, considering the inclusion of younger women is not only incomplete but has little bearing on the demographic group that is most at risk. She contends that early testing may serve to promote risk awareness to the point of causing anxiety for patients, rather than reducing cancer risk.
The potential psychological repercussions of being misdiagnosed or unduly tested were also highlighted, concerning the fact that fear may usurp genuine health education or promotion of frivolous health treatments.
Reevaluating Public Health Strategies
Dr. Maya Valecha champions a reassessment of how cervical cancer prevention and education are put across to the public. She questioned whether HPV vaccines marketed simply as preventative vaccines without any commentary on the multifactorial nature of cancer is even prudent.
One major theme through her discourse is the need for transparency around health statistics and exercising a holistic approach to women’s health that addresses nutrition and education in a way that prioritizes these factors with respect to the plight of sensational campaigns.
Final Note: Dr. Maya Valecha provided some food for thought concerning the complexity of cervical cancer statistics, the age of onset, and the complexity of thinking about public health strategies. This will allow people to think from many angles about statistically possible severity without judgment. The value in Dr. Maya Valecha’s comments is that good quality discussions will align with evidence and avoid sensationalized hysteria.
Also Read: